Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RBD2080 in Healthy Participants
NCT07869940Phase 1Recruiting
- Sponsor
- Suzhou Ribo Life Science Co., Ltd.
- Start
- Aug 2026
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of RBD2080 in complement-mediated disease (4 arms), sponsored by Suzhou Ribo Life Science Co., Ltd. Primary endpoint: Adverse Events at Day 113. Started Aug 2026; status: recruiting.
02
Drugs
RBD2080
03
Conditions
complement-mediated disease
Beyond the preview
Go deeper on NCT07869940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07869940.